See more : Nawi Brothers Group Ltd (NAWI.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Akebia Therapeutics, Inc. (AKBA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akebia Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Serco Group plc (SCGPY) Income Statement Analysis – Financial Results
- PNE AG (PNE3.DE) Income Statement Analysis – Financial Results
- Tyro Payments Limited (TYR.AX) Income Statement Analysis – Financial Results
- ToughBuilt Industries, Inc. WT EXP 110923 (TBLTW) Income Statement Analysis – Financial Results
- Ipca Laboratories Limited (IPCALAB.NS) Income Statement Analysis – Financial Results
Akebia Therapeutics, Inc. (AKBA)
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.62M | 292.60M | 213.58M | 295.31M | 335.00M | 207.74M | 177.98M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 74.15M | 84.80M | 153.39M | 295.91M | 145.34M | 7.69M | 617.00K | 115.79M | 96.00K | 23.26M | 0.00 | 0.00 |
| Gross Profit | 120.47M | 207.81M | 60.18M | -601.00K | 189.67M | 200.06M | 177.37M | -114.25M | -96.00K | -23.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 61.90% | 71.02% | 28.18% | -0.20% | 56.62% | 96.30% | 99.65% | -7,443.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 63.08M | 129.11M | 147.85M | 218.49M | 322.97M | 291.07M | 230.89M | 115.79M | 43.02M | 25.40M | 10.78M | 5.63M |
| General & Administrative | 0.00 | 141.87M | 177.65M | 157.36M | 152.98M | 87.13M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Selling & Marketing | 100.23M | -3.18M | 174.16M | 153.95M | 149.46M | 87.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.23M | 141.87M | 174.16M | 153.95M | 149.46M | 87.06M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Other Expenses | 3.42M | -12.54M | 3.49M | 3.41M | 3.53M | 6.24M | 204.00K | -188.00K | 287.00K | 700.00K | 1.05M | 1.97M |
| Operating Expenses | 166.73M | 270.99M | 325.50M | 375.84M | 475.95M | 378.20M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Cost & Expenses | 240.88M | 355.78M | 478.90M | 671.75M | 621.29M | 385.88M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Interest Income | 0.00 | 15.69M | 19.95M | 8.92M | 2.19M | 6.15M | 2.80M | 901.00K | 0.00 | 0.00 | 0.00 | 1.64M |
| Interest Expense | 6.03M | 15.69M | 19.94M | 8.87M | 1.40M | 6.15M | 0.00 | 0.00 | 510.00K | 206.00K | 703.57K | 0.00 |
| Depreciation & Amortization | 37.63M | 35.28M | 36.13M | 33.59M | 36.42M | 2.42M | 617.00K | 296.00K | 96.00K | 49.00K | 1.28K | 39.16K |
| EBITDA | -6.87M | -43.26M | -225.96M | -341.00M | -247.64M | -178.09M | -76.06M | -136.16M | -61.42M | -37.89M | -12.46M | -6.55M |
| EBITDA Ratio | -3.53% | -15.84% | -124.23% | -127.47% | -85.46% | -85.75% | -44.55% | -8,870.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.26M | -63.18M | -265.32M | -376.44M | -286.29M | -178.14M | -79.92M | -136.46M | -61.51M | -37.94M | -15.93M | -8.52M |
| Operating Income Ratio | -23.77% | -21.59% | -124.23% | -127.47% | -85.46% | -85.75% | -44.90% | -8,889.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.67M | -13.45M | -17.52M | -5.63M | -2.00K | 6.24M | 3.00M | 713.00K | 497.00K | 906.00K | 2.77M | 327.00K |
| Income Before Tax | -51.93M | -92.56M | -282.84M | -383.46M | -286.29M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Income Before Tax Ratio | -26.68% | -31.63% | -132.43% | -129.85% | -85.46% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.45M | -37.97M | -33.59M | -6.63M | -28.34M | -2.80M | -901.00K | -510.00K | -206.00K | 1.75M | 1.60M |
| Net Income | -51.93M | -106.01M | -244.87M | -349.87M | -279.66M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Net Income Ratio | -26.68% | -36.23% | -114.65% | -118.48% | -83.48% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| EPS Diluted | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| Weighted Avg Shares Out | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
| Weighted Avg Shares Out (Dil) | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Secures $55 Million Term Loan Financing
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports